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philic esophagitis (EoE) is limited to off-label use of cortico-
steroids not optimized for esophageal delivery. We performed a
randomized, controlled phase 2 trial to assess the ability of
budesonide oral suspension (BOS), a novel muco-adherent
topical steroid formulation, to reduce symptoms and esopha-
geal eosinophilia in adolescents and adults with EoE.
METHODS: In this multicenter, randomized, double-blind,
placebo-controlled, parallel-group trial, 93 EoE patients
between the ages of 11 and 40 years with dysphagia and active
esophageal eosinophilia were randomized to receive either BOS
2 mg or placebo twice daily for 12 weeks. Co-primary outcomes
were change in Dysphagia Symptom Questionnaire (DSQ) score
from baseline, and proportion of patients with a histologic
response (6 eosinophils/high-power ﬁeld) after treatment.
Endoscopic severity scores and safety parameters were
assessed. RESULTS: At baseline, mean DSQ scores were 29.3
and 29.0, and mean peak eosinophil counts were 156 and 130
per hpf in the BOS and placebo groups, respectively. After
treatment, DSQ scores were 15.0 and 21.5, and mean peak
eosinophil counts were 39 and 113 per high-power ﬁeld,
respectively (P < .05 for all). For BOS vs placebo, change in DSQ
score was 14.3 vs 7.5 (P ¼ .0096), histologic response rates
were 39% vs 3% (P < .0001), and change in endoscopic
severity score was 3.8 vs 0.4 (P < .0001). Adverse events
were similar between groups. CONCLUSIONS: Treatment with
BOS was well tolerated in adolescent and young adult patients
with EoE and resulted in improvement in symptomatic, endo-
scopic, and histologic parameters using validated outcome
instruments. ClinicalTrials.gov ID NCT01642212.Abbreviations used in this paper: ANCOVA, analysis of covariance; BOS,
budesonide oral suspension; CI, conﬁdence interval; DSQ, Dysphagia
Symptom Questionnaire; EoE, eosinophilic esophagitis; eos/hpf, eosino-
phils per high-power ﬁeld; EREFS, Endoscopic Reference Score; OR,
odds ratio; PPI, proton pump inhibitor; PRO, patient-reported outcome;
SD, standard deviation.
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http://dx.doi.org/10.1053/j.gastro.2016.11.021Eimmune-mediated condition characterized clinically
by symptoms of esophageal dysfunction and histologically
by eosinophilic inﬁltration of the esophageal mucosa.1–3Typical symptoms include dysphagia and food impaction
in adolescents and adults, and heartburn, regurgitation,
vomiting, and feeding intolerance in children.4 Over the past
2 decades, EoE has rapidly emerged as a major cause of
upper gastrointestinal morbidity, and it is now the most
common cause of food bolus impaction5,6 and the second
most common cause of esophagitis.7–9 The incidence and
prevalence of EoE are increasing,8,10,11 and health care
expenditure related to EoE in the United States approaches
$1 billion annually.12
Corticosteroids are the ﬁrst-line pharmacologic therapy
for patients diagnosed with EoE.1,2,13,14 These medications
are used topically: asthma preparations are swallowed
rather than inhaled to coat the esophagus, but are subop-
timal for use in EoE. For example, inadequate esophageal
delivery and undesired pulmonary deposition can result
from medication administered into the mouth using
metered-dose inhalers, and variable drug concentrations are
possible when patients mix aqueous forms into viscous
slurries.13,15 Although data support the use of both
ﬂuticasone16–24 and budesonide,15,25–30 neither are
approved by the Food and Drug Administration for this
indication. In addition, although these agents can decrease
or resolve esophageal eosinophilia, symptom response
has been inconsistent.13,15,20,21,29–31 In addition, published
trials have not evaluated EoE symptoms using a validated
patient-reported outcome (PRO) measure.32,33
Budesonide oral suspension (BOS) is a novel muco-
adherent medication formulated speciﬁcally for use in
EoE, with standardized viscosity and concentration. It has





ATpreviously been shown to induce a dose-dependent histo-
logic response in children with EoE,29 but has not been
assessed in adults. The aim of this phase 2 study was to
determine whether BOS was superior to placebo in
decreasing symptoms of dysphagia, as measured by a vali-
dated instrument, and decreasing esophageal eosinophil
counts in adolescents and adults with EoE.
Materials and Methods
Study Design and Participants
This was a multicenter, randomized, double-blind, placebo-
controlled, parallel-group phase 2 trial conducted from July
2012 to October 2014 at 25 centers throughout the United
States (see Supplementary Material). The study was approved
by the Institutional Review Board at each center, registered at
ClinicalTrials.gov (NCT01642212), performed in accordance
with the provisions of the Declaration of Helsinki, and reported
per the CONSORT (Consolidated Standards of Reporting Trials)
statement. Participants or parents/legal guardians provided
written informed consent before taking part in the study.
Participants did not receive a stipend from the study sponsor.
Potential study participants were aged 1140 years. The
lower bound of the age range was selected as this was
considered to be the minimum age at which patients would be
able to self-assess dysphagia, understand the Dysphagia
Symptom Questionnaire (DSQ) and complete the daily DSQ
entries. The upper bound of the age range was chosen as, at the
time of the study design, it was felt to be the most appropriate
cutoff to exclude older patients who are more likely to have
ﬁbrostenotic disease and typically are not amenable to anti-
inﬂammatory treatment alone.31,34 Patients aged younger
than 18 years were also included in this study, as the previous
pediatric study did not measure symptom response using a
validated instrument.29 Study participants were also required
to have a conﬁrmed diagnosis of EoE using 2011 consensus
guidelines:1 speciﬁcally, symptoms of esophageal dysfunction
and at least 15 intra-epithelial eosinophils per high-power ﬁeld
(eos/hpf) (hpf area: 0.3 mm2) after an 8-week, high-dose (re-
fers to a total daily dose, which could be administered as a once
or twice daily dosing regimen), proton pump inhibitor (PPI)
trial using any approved PPI. The PPI trial was either historical
or could have been performed during the screening period of
this study; PPI-responsive EoE was deﬁned as <15 eos/hpf, as
recommended by the current guidelines.1 Other potential
causes of esophageal eosinophilia had also been excluded. For
inclusion, patients with EoE were required to have at least
15 eos/hpf from at least 2 esophageal levels on screening
endoscopy, at least 4 days with symptoms of dysphagia over
the last 2 weeks of a 4-week blinded placebo run-in period, and
at least 70% compliance with a daily symptom diary. The
purpose of these criteria was to include patients with active
EoE who were highly symptomatic and whose symptoms per-
sisted during the placebo run-in period. The exclusion criteria
included presence of any of the following: non-EoE gastroin-
testinal diseases, including eosinophilic gastroenteritis/colitis,
inﬂammatory bowel disease, celiac disease, Helicobacter pylori
infection, esophageal candidiasis (deﬁned based on investigator
discretion), or esophageal varices; diseases causing systemic
eosinophilia; or esophageal stricture on screening endoscopy
that precluded passage of an adult upper endoscope.Gastroesophageal reﬂux disease and erosive esophagitis were
not formal exclusion criteria, but patients with esophageal
eosinophilia related to gastroesophageal reﬂux disease were
excluded, as based on PPI-responsive eosinophilia. Other
exclusion criteria were: use of corticosteroids (topical or sys-
temic) in the 4 weeks preceding the screening endoscopy; use
of immunomodulatory therapy in the 8 weeks preceding the
screening endoscopy; change in dosing regimen of PPIs, allergy
medications, or inhaled corticosteroids; pregnancy; and medi-
cal instability.
Randomization, Interventions, and Outcomes
After a screening upper endoscopy and biopsy, symptoms
were assessed during a 4-week placebo-run-in period, during
which all patients received single-blind placebo. If patients met
histology and symptom eligibility criteria, they were random-
ized 1:1 to either BOS 2 mg twice daily (given as 10 mL, once in
the morning after breakfast and once in the evening before
bedtime to provide a total daily dose of 4 mg), or a placebo
suspension twice daily, for 12 weeks. BOS is formulated in a
viscous suspension designed to increase the time the drug is in
contact with the surface of the esophagus after swallowing. The
pre-mixed suspension uses a combination of 2 viscosity-
modifying agents to give the suspension a syrup-like consis-
tency (as opposed to a slurry), along with buffers,
preservatives, and ﬂavoring agents. Patients were instructed
not to eat, drink, brush their teeth or rinse their mouth for
30 minutes after taking BOS. After 30 minutes, patients were
instructed to rinse their mouth with water.
The randomization schedule was generated by Synter-
actHCR, Inc. and was veriﬁed for accuracy using strict quality-
control procedures. Randomization was stratiﬁed by site with a
block size of 4. Participants eligible for randomization received
sequentially generated randomization numbers issued by
Clinical Supplies Management, Inc., which were matched to the
number on their study drug kit. The randomization number
was not used to identify a patient’s study data. Instead, all
patients were assigned a unique 6-digit patient identiﬁcation
number at screening. Participants, investigators, the sponsor,
study site personnel, and the central pathologist were blinded
to patients’ treatment, until after all patients had completed the
treatment period and the database was locked. Treatment
assignment was only to be unblinded in a situation where
unblinding was absolutely necessary for the management of
patient safety or for regulatory reporting purposes to the Food
and Drug Administration. However, no patients required
treatment assignment unblinding before the database lock in
this study. Active study medication and placebo were dispensed
in identical amber glass bottles to maintain the blind.
Compliance was measured by residual volume in the
medication bottles. At the end of the treatment period, repeat
endoscopy and biopsy were performed. The co-primary out-
comes were the change in DSQ score from baseline; and
the proportion of patients with a histologic response, deﬁned as
6 eos/hpf. This cutoff of 6 eos/hpf was used in the previous
pediatric study of BOS,29 and is supported by a number of
studies in the literature.35,36 Secondary end points included
endoscopic ﬁndings and safety.
The DSQ is a 3-question daily diary that has been validated
for the measurement of dysphagia frequency and severity in
patients with EoE.37,38 The questions ask whether solid food
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stuck; and what, if any, measures have been taken to achieve
relief. DSQ scores are calculated on the basis of the responses to
these questions over a 2-week period. The scores for questions
2 and 3 are summed, then divided by the number of days for
which the diary has been completed and multiplied by 14.
Scores can range from 0 to 84, with higher values indicating
more frequent and severe dysphagia. A DSQ score of 0 repre-
sents an absence of dysphagia symptoms. DSQ scores over the
last 14 days of the 12-week treatment period were used for the
symptom outcome measure using the algorithm above. Two
prespeciﬁed secondary end points were also examined: the
proportion of patients with a 30% or a 50% reduction in
DSQ score from baseline; and 2) patients who had this
symptom response combined with a histologic response
(6 eos/hpf).
For histology assessment, 2 to 4 esophageal biopsies were
obtained from each level of the esophagus (proximal, mid, and
distal). Biopsies were reviewed centrally by the study pathol-
ogist (M.H.C., who was blinded to treatment allocation). All
biopsies from each site in the esophagus were examined, and
intraepithelial eosinophils were counted in the areas of greatest
eosinophil density.39 Counts were reported as the number of
eos/hpf (hpf area ¼ 0.3 mm2) and multiple hpfs were analyzed
until the peak count was clearly identiﬁed. In addition, gastric
and duodenal biopsies were obtained and reviewed
centrally during the screening period to exclude patients with
concomitant eosinophilic gastroenteritis.
Upper endoscopy was performed using standard tech-
niques. Endoscopic ﬁndings (esophageal rings, white plaques or
exudates, linear furrows, decreased vascularity or edema, and
strictures) were recorded and quantiﬁed using the validated
EoE Endoscopic Reference Score (EREFS);40 esophageal bi-
opsies were obtained at the same time. The total EREFS was
calculated by summing the severity scores of the individual
components of the EREFS (edema 02, rings 03, exudates
02, furrows 02, strictures 01) assessed for both the
proximal and distal esophagus, and ranged from 0 to 20, with
higher scores indicating more severe endoscopic ﬁndings.
Safety was assessed at each study visit by carrying out a
physical examination and recording height, weight, and vital
signs. Clinical laboratory tests were also performed, including
assessment of a morning cortisol level to monitor the adrenal
axis. Patients received a follow-up telephone call 4 weeks after
receiving their last dose of the study drug. All clinical labora-
tory tests were performed by a centralized clinical laboratory
(LabConnect, LLC).
Statistical Analyses
Data were collected by investigators at each site and the
database was managed by the study sponsor. All authors had
access to the study data and reviewed and approved the ﬁnal
manuscript. There were 2 analysis sets. The safety analysis set
included all patients who received any study drug. The modi-
ﬁed intention-to-treat analysis set included all randomized
patients who received at least 1 dose of study drug and had
both an evaluable post-treatment DSQ score and a post-
treatment biopsy. Characteristics of the treatment and pla-
cebo arms were summarized with descriptive statistics. The
change in DSQ score and change in EREFS were each compared
using analysis of covariance, and the proportion of patientswith a histologic response was compared using Fisher’s exact
test. We also compared levels of symptom, histologic, and
endoscopic response using Fisher’s exact test. For exploratory
analyses based on histologic response, odds ratios (for cate-
gorical variables) and differences (for continuous variables)
with 95% conﬁdence intervals were calculated.
The planned sample size was to have at least 40 patients in
each arm complete the study. This would yield >90% power to
detect an 88% difference in histologic response,29 and 89%
power to detect a 35% difference in symptom response.
Assuming a 20% dropout rate, the goal was to enroll 50
patients in each arm.
Role of the Funding Source
Meritage Pharma, Inc, now part of the Shire group of
companies, contributed to the design and conduct of the study;
collection and management of the data; and reviewed the
manuscript for medical accuracy. Approval of the manuscript,
and the decision to submit the manuscript for publication was
the responsibility of the authors.Results
Patient Flow and Baseline Characteristics
Of the 203 patients screened, 119 met eligibility criteria
and entered the blinded placebo run-in period. Of these, 26
were excluded, primarily for experiencing dysphagia on too
few days, and 93 were randomized, 51 to BOS and 42 to
placebo. This group comprised the safety analysis set. Of the
randomized patients, 5 dropped out, 2 in the BOS arm
(1 because of an adverse event and 1 owing to lack of
compliance) and 3 in the placebo arm (1 because of lack of
efﬁcacy, 1 because of lack of compliance, and 1 owing to
pregnancy); 1 additional patient in the placebo arm did not
have an evaluable post-treatment biopsy. Therefore, 87
were included in the outcome analysis set (49 on BOS and
38 on placebo) (Supplementary Figure 1).
The BOS and placebo groups had similar baseline char-
acteristics (Table 1). The BOS and placebo groups also had a
similarly high prevalence of endoscopic ﬁndings, such as
esophageal rings (61% and 64%), white plaques (73% and
69%), linear furrows (94% and 86%), and edema (80% and
76%, respectively). Compliance with study medication was
high in both the BOS and the placebo groups, with 86% and
88% receiving the intended dose.
Symptomatic, Histologic, and Endoscopic
Outcomes
The baseline mean DSQ scores were 29.3 in the BOS
group and 29.0 in the placebo group. After treatment, these
decreased to 15.0 and 21.5, respectively. There was a
signiﬁcantly larger decrease in the BOS group (14.3) than
the placebo group (7.5; P ¼ .0096) (Table 2; Figure 1A).
The ﬁrst of the co-primary end points was therefore met.
When examining symptom thresholds (prespeciﬁed sec-
ondary end point), 34 patients (69%) in the BOS group had
a 30% reduction in DSQ score compared with 17 patients
(45%) in the placebo group (P ¼ .021). Similarly, 31
Table 1.Demographics and Baseline Measures in Patients
With Eosinophilic Esophagitis Receiving Budesonide






Age, y, mean ± SD 22.3 ± 7.9 20.8 ± 7.5
Younger than 18 y, n (%) 18 (35) 17 (41)
Age of those younger
than 18 y, mean ± SD
14.6 ± 2.2 13.6 ± 1.6
Male, n (%) 35 (69) 29 (69)
White, n (%) 48 (94) 40 (95)
Months since EoE
diagnosis, mean ± SD
38.5 ± 34.3 36.5 ± 42.6
Height, cm, mean ± SD 173.6 ± 9.9 170.7 ± 13.0
Weight, kg, mean ± SD 72.0 ± 16.9 67.8 ± 17.3
Previous medication, n (%)
Corticosteroids 14 (28) 13 (31)
Systemic, oral 2 (4) 2 (5)
Systemic, intravenous 5 (10) 5 (12)
Inhaled 2 (4) 4 (10)
Intranasal 7 (14) 6 (14)
Antihistamines 8 (16) 3 (7)
Leukotriene antagonists 6 (12) 6 (14)
Proton pump inhibitors
Past 35 (69) 29 (69)
Current 36 (71) 28 (67)
Endoscopic ﬁndings, n (%)
Normal 1 (2) 2 (5)
Esophageal rings 31 (61) 27 (64)
White plaques or exudates 37 (73) 29 (69)
Linear furrows 48 (94) 36 (86)
Edema or decreased vascularity 41 (80) 32 (76)
Esophageal stricture 7 (14) 4 (10)
Total EREFS, mean ± SDa 7.7 ± 3.5 7.0 ± 3.3
DSQ score, mean ± SDb 30.4 ± 15.9 29.0 ± 13.5
Peak eosinophil counts,
eos/hpf, mean ± SD
Overall 157.8 ± 96.1 133.0 ± 81.6
By esophageal location
Proximal 100.9 ± 99.6 53.4 ± 58.5
Mid 103.8 ± 67.5 94.4 ± 80.5
Distal 107.4 ± 79.5 95.6 ± 74.8
aThe total EREFS was calculated by summing the scores for
the 5 major individual ﬁndings (grade 03 for esophageal
rings; grade 02 for white plaques or exudates, edema or
decreased vascularity, and linear furrows; and grade 01 for
esophageal stricture) from both the proximal and distal
esophagus.
bDSQ score calculated based on patient responses to
questions 2 and 3 of the questionnaire (frequency and in-
tensity of dysphagia) over a 2-week period. Scores from
these questions were summed, divided by number of days for
which the diary was completed, and multiplied by 14 (days).
Scores could range from 0 to 84.
Table 2.Baseline and Post-Treatment Measures in Patients
With Eosinophilic Esophagitis Receiving Budesonide








DSQ score, mean ± SDa
Baseline 29.3 ± 15.1 29.0 ± 13.9
Post-treatment 15.0 ± 16.9 21.5 ± 16.0
Difference 14.3 ± 13.0 7.5 ± 10.7 .0096
Proportion of histologic
responders, n (%)b
19 (39) 1 (3) <.0001
Peak eosinophil count,
eos/hpf, mean ± SD
Baseline 156.3 ± 97.6 130.2 ± 81.8
Post-treatment 39.3 ± 48.1 112.9 ± 84.3
Difference 117.0 ± 111.6 17.3 ± 83.8 <.0001
EREFS, mean ± SDc
Baseline 7.7 ± 3.6 6.9 ± 3.4
Post-treatment 3.9 ± 3.3 7.3 ± 4.0
Difference 3.8 ± 3.9 0.4 ± 6.7 <.0001
aDSQ score calculated based on patient responses to
questions 2 and 3 of the questionnaire (frequency and in-
tensity of dysphagia) over a 2-week period. Scores from
these questions were summed, divided by number of days for
which the diary was completed, and multiplied by 14 (days).
Scores could range from 0 to 84.
bProportion of histologic responders post-treatment; histo-
logic response deﬁned as 6 eos/hpf.
cThe total EREFS was calculated by summing the scores for
the 5 major individual parameters (grade 03 for esophageal
rings; grade 02 for white plaques or exudates, edema or
decreased vascularity, and linear furrows; and grade 01 for
esophageal stricture) from both the proximal and distal
esophagus.





ATpatients (63%) in the BOS group had a 50% reduction in
DSQ score compared with 15 patients (40%) in the placebo
group (P ¼ .028). The number of patients who experienced
complete symptom resolution (DSQ score 0) at week 12 was
reported as an exploratory outcome, and was higher in the
BOS group (20% [10 of 49]) than in the placebo group (13%
[5 of 38]).At baseline, the means of the peak eosinophil counts
were 156 eos/hpf in the BOS group and 130 eos/hpf in the
placebo group. Post-treatment, these were 39 and 113,
respectively (P < .0001; Table 2). The distribution of peak
eosinophil counts for patients in the BOS and placebo
groups at baseline (safety analysis set) by esophageal region
is shown in Supplementary Figure 2. A total of 19 patients
(39%) in the BOS group achieved the histologic response
end point of 6 eos/hpf, compared with 1 patient (3%) in
the placebo group (P < .0001) (Table 2; Figure 1B), thus
meeting the second of the co-primary end points. Illustrative
pre- and post-treatment biopsies are shown in Figure 2.
When examining additional histologic response thresholds,
a total of 23 patients (47%) in the BOS group had 15 eos/
hpf vs 3 (8%) in the placebo group (P ¼ .0001), and 15
(31%) patients in the BOS group had 1 eos/hpf vs none in
the placebo group (P < .0001).
An additional secondary efﬁcacy end point showed that
a higher proportion of patients in the BOS group had both a
histologic response and a 30% reduction in DSQ score
compared with patients in the placebo group (27% vs 3%;
P ¼ .0026); a higher proportion of patients receiving BOS
also experienced both a histologic response and a 50%
reduction in DSQ score compared with placebo (20% vs 3%;
P ¼ .0199).
Figure 1. Study outcomes in patients with eosinophilic
esophagitis receiving budesonide oral suspension vs pla-
cebo. (A) Change in DSQ score; (B) histologic outcomes; and
(C) endoscopic outcomes from baseline.
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and 6.9 in the placebo group. After treatment, these were
3.9 and 7.3, respectively. There was a signiﬁcantly larger
decrease in the BOS group (3.8) than in the placebo group
(0.4; P < .0001) (Table 2; Figure 1C). In addition to the
improvement in total EREFS, signiﬁcant improvements
within each EREFS component (with the exception of
strictures) from baseline were also observed for patients
receiving BOS compared with those receiving placebo
(Figure 3). The severity score for esophageal rings in the
BOS group decreased (improved) from 1.7 to 1.0, but was
unchanged in the placebo group (1.4 to 1.7) (change from
baseline: 0.7 vs þ0.3; P ¼ .006). Similarly, the severity
score for esophageal exudates in the BOS group decreased
from 1.6 to 0.4, but was unchanged in the placebo group(1.4 to 1.3) (change from baseline: 1.2 vs 0.1; P < .001).
Severity scores for furrows in the BOS group decreased
from 2.3 to 1.2 without a change in the placebo group (2.0 to
2.1) (change from baseline: 1.1 vs þ0.1; P < .0001.
Severity scores for edema in the BOS group decreased from
1.9 to 1.1, again without any change in the placebo group
(1.9 to 2.1) (change from baseline: 0.8 vs þ0.2; P ¼ .004)
(Figure 3). These scores were calculated from 2 levels of the
esophagus (proximal and distal); and the data are presented
by location in Supplementary Table 1. These results show an
improvement in endoscopic features in the BOS group from
baseline in both the proximal and distal regions of the
esophagus. Furthermore, a total of 7 patients (14%) in the
BOS group and 1 patient (3%) in the placebo group had
normal endoscopic ﬁndings (EREFS 0) after treatment.
Illustrative pre- and post-treatment endoscopic images are
shown in Figure 2.
Given that symptoms, histology, and endoscopic severity
all improved with BOS compared with placebo, we investi-
gated correlations between these responses. In the BOS
group, there was a weak correlation between change in peak
eosinophil count and change in DSQ score (R ¼ 0.04)
and between change in DSQ score and change in EREFS
(R ¼ 0.05), but a moderate correlation between change in
peak eosinophil count and change in EREFS (R ¼ 0.33).
Overall, clinical, endoscopic, and histologic baseline
characteristics were similar in patients treated with BOS
who did and did not have a histologic response (Table 3).
However, compared with histologic responders,
nonresponders had been diagnosed with the disease for
almost twice as long (46 vs 25 months) and were more than
10 kg heavier (76 vs 65 kg). Symptoms and endoscopic
ﬁndings improved more in histologic responders than
in nonresponders. The mean change in the DSQ score
was 16.2 in histologic responders and 9.9 in
nonresponders (P < .001). Similarly, the mean change in
total EREFS was 5.1 in histologic responders and 2.9
in nonresponders (P ¼ .06).Safety and Adverse Events
Reports of treatment-emergent adverse events were
similar in the BOS (47%) and placebo (50%) groups
(Supplementary Table 2). There was 1 severe adverse event
in the BOS group related to an episode of food poisoning
and deemed unrelated to the study drug, and a second
adverse event in the BOS group that led to withdrawal
because of chest pain, dyspnea, nausea, and vomiting, which
was deemed related to the study drug. Nasopharyngitis,
upper respiratory infection, and oropharyngeal pain were
the most commonly reported adverse events in both groups.
There was 1 case each of esophageal candidiasis and oral
candidiasis in the BOS group. There were no laboratory-
related treatment-emergent adverse events. Additionally,
there were no notable differences between groups in
cortisol levels (Supplementary Table 3) or growth charac-
teristics (for those aged younger than 18 years;
Supplementary Table 4), and vital signs remained stable for
all participants.
Figure 2. Baseline and post-treatment endoscopies with corresponding esophageal biopsies for 2 patients with eosinophilic
esophagitis receiving budesonide oral suspension. Pretreatment images show esophageal rings, linear furrows, and edema
(patient 1 [A]), and white plaques and edema (patient 2, [C]). Both biopsy specimens have elevated mucosal eosinophilia,
indicated by arrows (A, C). Post-treatment images show normalization of the esophageal mucosa and the epithelium (B, D).
Histology images: stained with H&E; 200 original magniﬁcation.






Topical corticosteroids are the ﬁrst-line pharmacologic
treatment option for patients with EoE, but none are Food
and Drug Administrationapproved or designed for EoE
and none have previously been assessed using a validated
PRO instrument.1,2,4,13,32,33 This multicenter, randomized,
double-blind, placebo-controlled, parallel-group phase 2
trial aimed to determine whether BOS was superior to
placebo in decreasing symptoms of dysphagia and esopha-
geal eosinophil counts. Not only did BOS induce a histologic
response in a signiﬁcantly higher proportion of patients
than placebo, we show for the ﬁrst time that it also signif-
icantly decreased symptoms of dysphagia as assessed by a
validated PRO instrument. Importantly, the decrease in
symptom score was clinically meaningful with dysphagia
being experienced on approximately 3 fewer days over
2 weeks in the BOS group than in the placebo group.
Furthermore, the study is the ﬁrst to demonstrate
improvement in endoscopic severity scores, assessed using
the validated EREFS instrument. In addition, patients with a
histologic response experienced greater improvements in
dysphagia symptoms and endoscopic severity compared
with nonresponders. No safety issues related to BOS were
identiﬁed during the 12-week treatment period, and
patients were highly compliant. There were only 2 cases of
esophageal candidiasis in patients receiving BOS; this islower than the reported rates in the literature for other
swallowed corticosteroids;28,30 however, this ﬁnding is
consistent with a previous study of this budesonide
formulation.29
Several formulations of budesonide have previously
been used in clinical trials, including a slurry created by
mixing an aqueous form with sucralose,15,27 a nebulized
form (allowing aerosolized droplets to be swallowed),15,28 a
pre-mixed viscous solution,29,30 and an effervescent
dissolvable tablet.30 Doses in these studies were 14 mg/d,
with treatment periods of 212 weeks. Histologic responses
were variable (27%100% depending on the age group,
formulation, and histologic response threshold studied) and
symptom response rates were equally variable. None of
these studies used a validated symptom instrument, and in
3 of the 5 trials there were discordant symptomatic and
histologic responses.15,29,30 In addition to these individual
studies, a number of systematic reviews/meta-analyses
have been performed to examine the efﬁcacy of current
pharmacologic treatments for EoE. These reviews have
shown that patients treated with topical corticosteroids
typically experience improvements in histologic outcomes
compared with placebo (or therapy control); however, a
clear symptom response is often less evident,4144 in
part due to the absence of a validated clinical outcome
assessment for EoE.
Figure 3. Baseline and post-treatment changes in endoscopic severity for individual components of the EREFS for patients
with eosinophilic esophagitis receiving budesonide oral suspension vs placebo. Findings for esophageal edema, rings, exu-
dates, furrows, and strictures are presented at baseline and post-treatment for the BOS and placebo groups. P values
compare change in scores from baseline between treatment arms.
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ATIn the previous study of BOS,29 children were treated
with age-based dosing, and of those receiving the highest
dose (2 mg twice daily), 94% had a histologic response
compared with 6% in the placebo group. The present study
had a lower histologic response rate than this. However, our
observed response rate is consistent with the range of
responses that have been reported for topical steroids
overall in the literature.15,18,19,21,27–30,45 The reasons for the
difference in histologic response observed in this study and
the previous study of BOS29 are not known, but earlier
studies of pediatric EoE have shown that age, body mass,
and height are predictors of steroid response.18 The lower
histologic response observed in the present study may also
be a result of the study design, in particular the inclusion
criteria. For enrollment in the current study, patients were
required to have active inﬂammation and also to be highly
symptomatic, with at least 4 days of dysphagia in the
2 weeks before study entry. In addition, patients had to
maintain this high level of symptomatology during a blinded
placebo run-in period in order to be randomized. They also
had to have eosinophilic inﬂammation at 2 levels in the
esophagus, a stringent inclusion criterion used only in theprevious BOS study.29 This probably resulted in a more
severe disease phenotype than seen in other studies,28–30
which might also have been more treatment resistant. For
example, the peak baseline eosinophil count in this study,
156.3 eos/0.3 mm2 hpf (or 521 eos/mm2) in the BOS arm, is
among the highest reported in the literature; in other
studies of budesonide using this as an outcome measure,
peak baseline eosinophil densities were 320421 eos/mm2
(after conversion of counts based on hpf area).15,29,30 To our
knowledge, no other published study has been designed to
enroll a comparably symptomatic and histologically severe
population of patients with EoE. Indeed, Eluri and
colleagues have recently identiﬁed disease severity as a
signiﬁcant predictor of response to steroids.46 Finally,
although a number of studies have reported high (>90%)
histologic response rates in patients receiving topical
corticosteroids,29,30 no statistically signiﬁcant difference in
symptom response compared with placebo was observed in
these earlier studies.
We found few predictors of histologic response; only
shorter disease duration and lower body weight were
associated with response. However, these results may have
Table 3.Comparison of Baseline Characteristics in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral
Suspension According to Histologic Response (6 eos/hpf)
Characteristic
Patients with histologic responsea
Responders (n ¼ 19) Nonresponders (n ¼ 30) OR or difference (95% CI)
Age, y, mean ± SD 22.5 ± 7.7 21.7 ± 7.6 0.9 (3.7 to 5.4)
Younger than 18 y, n (%) 8 (42) 10 (33) 0.69 (0.21 to 2.25)
Male, n (%) 11 (58) 24 (80) 2.91 (0.81 to 10.4)
White, n (%) 16 (84) 30 (100) —
Time since EoE diagnosis, mo, mean ± SD 25.2 ± 22.3 45.5 ± 36.8 20.3 (39.9 to 0.8)
Height, cm, mean ± SD 172.5 ± 8.3 174.8 ± 11.0 2.4 (8.3 to 3.5)
Weight, kg, mean ± SD 64.6 ± 10.5 76.4 ± 18.4 11.7 (21.0 to 2.3)
Previous medication, n (%)
Corticosteroids (any) 5 (26) 9 (30) 1.20 (0.33 to 4.34)
Antihistamines 5 (16) 4 (13) 0.82 (0.16 to 4.15)
Leukotriene antagonists 1 (5) 5 (17) 3.60 (0.39 to 33.5)
Current proton pump inhibitors 15 (79) 20 (67) 0.53 (0.14 to 2.03)
Endoscopic ﬁndings, n (%)
Esophageal rings 10 (53) 20 (67) 1.80 (0.55 to 5.84)
White plaques or exudates 15 (79) 20 (67) 0.53 (0.14 to 2.03)
Linear furrows 18 (95) 28 (93) 0.78 (0.07 to 9.22)
Edema or decreased vascularity 14 (74) 25 (83) 1.79 (0.44 to 7.25)
Esophageal stricture 2 (11) 5 (17) 1.70 (0.29 to 9.80)
Total EREFS, mean ± SDb 7.4 ± 3.7 7.8 ± 3.6 0.4 (2.5 to 1.8)
DSQ score, mean ± SDc 30.9 ± 15.1 28.2 ± 15.3 2.6 (6.3 to 11.6)
Peak eosinophil counts, eos/hpf, mean ± SD
Overall 154.2 ± 98.0 157.7 ± 99.0 3.5 (61.7 to 54.6)
By esophageal location
Proximal 86.7 ± 78.8 104.1 ± 113.0 17.4 (78.0 to 43.2)
Mid 102.9 ± 50.3 106.1 ± 78.6 3.2 (45.2 to 38.9)
Distal 113.1 ± 96.2 105.2 ± 71.2 7.8 (40.3 to 56.0)
By baseline eosinophil count, n (%)
>50 eos/hpf 19 (100) 27 (90) —
>100 eos/hpf 11 (58) 21 (70) 1.70 (0.51 to 5.63)
aHistologic responders deﬁned as 6 eos/hpf; nonresponders deﬁned as >6 eos/hpf.
bThe total EREFS was calculated by summing the scores for the 5 major individual ﬁndings (grade 03 for esophageal rings;
grade 02 for white plaques or exudates, edema or decreased vascularity, and linear furrows; and grade 01 for esophageal
stricture) from both the proximal and distal esophagus.
cDSQ score calculated based on patient responses to questions 2 and 3 of the questionnaire (frequency and intensity of
dysphagia) over a 2-week period. Scores from these questions were summed, divided by number of days for which the diary
was completed, and multiplied by 14 (days). Scores could range from 0 to 84.





ATbeen found by chance, and as such, may not reﬂect a true
difference between responders and nonresponders. As
mentioned previously, lower body weight, shorter stature,
and younger age were identiﬁed as predictors in a pediatric
study using topical ﬂuticasone.18 There are few published
data on predictors of response to topical budesonide. In
1 large retrospective study,45 esophageal dilation was
associated with nonresponse, and other studies have shown
that the prevalence of esophageal strictures (and hence the
need for dilation) increased with increasing disease dura-
tion.47,48 Additionally, we observed no statistically signiﬁ-
cant difference in EREFS between responders and
nonresponders at baseline, which is consistent with the
study by van Rhijn and colleagues,49 which identiﬁed limi-
tations in the correlation between EREFS and histologic
remission.
Limitations of this study include a restricted age range
(1140 years), so results may not be applicable to youngchildren or older adults. There was also an imbalance with
regards to patient numbers after randomization (BOS,
n ¼ 51; placebo, n ¼ 42), which was due to the site strati-
ﬁcation method used (block size of 4), a site randomization
error that occurred at 2 of the sites (these 2 sites skipped
random numbers in error), and a number of sites only
enrolling 1 patient per site. Speciﬁcally, there were 5 sites
where only 1 patient was enrolled and 3 sites where there
was an imbalance (of 13 patients per site). Patients with
severe strictures were excluded at screening to avoid
esophageal dilation as a confounder to symptom response;
although patients with mild strictures were included,
none of these patients developed severe strictures during
the 12-week treatment period. It should also be noted that
patients were allowed to remain on a stable dose of PPI
during the trial, which could have impacted the treatment
effect size. However, this would have been unlikely to
introduce bias, as patients in the BOS and placebo groups
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AThad similar levels of PPI use. Finally, although the 12-week
treatment period is longer than some previous trials,28,30
long-term efﬁcacy data are needed. This study was not
powered to assess treatment effect by age (ie, adolescents
vs adults); however, this would be useful to examine in
future studies of BOS.
A key strength of the study is that this was a rigorously
conducted, multicenter, randomized, blinded, placebo-
controlled, parallel-group trial that is the largest study of
topical corticosteroids to date in patients with EoE. The
strict inclusion criteria yielded a histologically severe and
symptomatic population of patients with EoE. Safety moni-
toring was comprehensive. Finally, this is the ﬁrst trial to
use validated symptom and endoscopy outcome measures
speciﬁcally developed for EoE,37,40 as well as the ﬁrst
to show improvement in symptomatic, endoscopic, and
histologic outcomes. Recent clinical trials of topical steroids
in EoE have failed to show this relationship with non-
validated symptom measures.29,30 These design elements,
including the blinded placebo run-in period, should help to
inform future therapeutic trials in EoE.
In conclusion, compared with placebo, 12 weeks of BOS
treatment signiﬁcantly improved both esophageal eosino-
philia and symptoms of dysphagia in adolescents and adults
with active EoE. There were no unexpected safety signals,
and compliance with medication was high, suggesting that
this formulation can be reliably used. In addition, this is the
ﬁrst prospective study to use a validated PRO instrument
and a validated endoscopy classiﬁcation to demonstrate
improvement in dysphagia symptoms and endoscopic
severity scores. BOS is therefore a promising formulation for
treatment of EoE.Supplementary Material
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Supplementary Figure 1. CONSORT (Consolidated Standards of Reporting Trials) diagram showing patient ﬂow. Of 203
screened, 119 met initial eligibility criteria. The majority of those who were ineligible did not meet histologic or symptom
thresholds. Of the 119 eligible, 26 were excluded, primarily for experiencing dysphagia on too few days. In total, 93 participants
were randomized and comprised the safety analysis set. Of these, 87 patients were included in the outcome analysis set.
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Supplementary Figure 2. Distribution of mean peak eosino-
phil counts by esophageal region and their mean maximum
counts for patients receiving budesonide oral suspension (A)
or placebo (B) (safety analysis set). Boxplots show mean
(diamond), median (middle line), interquartile ranges ([IQR];
top and bottom edges of box), minimum and maximum
values (error bars, within 1.5  IQR), and values considered to
be outliers (circles, values < or >1.5  IQR).
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Supplementary Table 1.Baseline and Post-Treatment Total Endoscopic Reference Score and Individual Component Scores
From Proximal and Distal Regions of the Esophagus in Patients With Eosinophilic Esophagitis
Receiving Budesonide Oral Suspension or Placeboa
Proximal Distal
BOS (n ¼ 49) Placebo (n ¼ 38) P value BOS (n ¼ 49) Placebo (n ¼ 38) P value
EREFSb
Baseline 3.4 ± 2.2 3.3 ± 2.0 4.3 ± 1.9 3.6 ± 1.6
Post-treatment 1.5 ± 1.8 3.4 ± 2.2 2.4 ± 1.8 3.9 ± 2.2
Difference 1.8 ± 2.2 0.1 ± 2.2 .0001 1.9 ± 2.1 0.3 ± 2.0 <.0001
Fixed rings
Baseline 0.8 ± 0.8 0.7 ± 0.7 0.8 ± 0.8 0.7 ± 0.7
Post-treatment 0.4 ± 0.7 0.9 ± 0.9 0.6 ± 0.8 0.8 ± 0.8
Difference 0.4 ± 0.7 0.2 ± 0.8 .0046 0.2 ± 0.8 0.1 ± 0.9 .1394
Exudates
Baseline 0.7 ± 0.7 0.7 ± 0.7 0.9 ± 0.7 0.8 ± 0.7
Post-treatment 0.2 ± 0.5 0.6 ± 0.8 0.2 ± 0.5 0.8 ± 0.8
Difference 0.6 ± 0.8 0.1 ± 0.9 .0142 0.6 ± 0.8 0.0 ± 0.8 .0006
Furrows
Baseline 1.0 ± 0.7 1.0 ± 0.6 1.4 ± 0.6 1.1 ± 0.6
Post-treatment 0.4 ± 0.7 0.9 ± 0.7 0.8 ± 0.7 1.2 ± 0.7
Difference 0.6 ± 0.7 0.0 ± 0.7 .0007 0.6 ± 0.7 0.2 ± 0.7 <.0001
Edema
Baseline 0.8 ± 0.7 0.9 ± 0.8 1.1 ± 0.7 1.0 ± 0.7
Post-treatment 0.4 ± 0.7 0.9 ± 0.7 0.7 ± 0.7 1.2 ± 0.7
Difference 0.3 ± 0.8 0.0 ± 0.7 .0281 0.4 ± 0.8 0.2 ± 0.7 .0012
Strictures
Baseline 0.0 ± 0.2 0.1 ± 0.2 0.1 ± 0.4 0.1 ± 0.3
Post-treatment 0.0 ± 0.2 0.1 ± 0.3 0.1 ± 0.3 0.1 ± 0.3
Difference 0.0 ± 0.3 0.0 ± 0.3 .6698 0.0 ± 0.3 0.0 ± 0.2 .4470
NOTE. Values are expressed as mean ± SD unless otherwise indicated.
ANCOVA, analysis of covariance.
aEstimates were determined using an ANCOVA model including treatment group and baseline value as a covariate.
bThe total EREFS was calculated by summing the scores for the 5 major individual parameters (grade 03 for esophageal
rings; grade 02 for white plaques or exudates, edema or decreased vascularity, and linear furrows; and grade 01 for
esophageal stricture).
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Supplementary Table 2.Treatment-Emergent Adverse Events in Patients Receiving Budesonide Oral Suspension or Placebo
TEAE BOS (n ¼ 51) Placebo (n ¼ 42)
All TEAEs 24 (47) 21 (50)
TEAEs related to study drug 5 (10) 4 (10)
Severe TEAEs 1 (2)a 0 (0)
Serious adverse events 1 (2) 0 (0)
TEAEs leading to withdrawal from study 1 (2) 0 (0)
TEAEs related to study drug and leading to withdrawal from study 1 (2)b 0 (0)
Infections and infestations 13 (25) 7 (17)
Nasopharyngitis 3 (6) 4 (10)
Upper respiratory tract infection 3 (6) 2 (5)
Sinusitis 2 (4) 1 (2)
Clostridium difﬁcile infection 1 (2) 0 (0)
Oral candidiasis 1 (2) 0 (0)
Esophageal candidiasis 1 (2) 0 (0)
Gastrointestinal disorders 3 (6) 9 (21)
Diarrhea 0 (0) 1 (2)
Food poisoning 2 (4) 0 (0)
Vomiting 1 (2) 1 (2)
Abdominal pain/discomfort 0 (0) 3 (7)
Respiratory disorders 6 (12) 3 (7)
Oropharyngeal pain 2 (4) 2 (5)
Cough 1 (2) 0 (0)
Dyspnea 1 (2) 0 (0)
Allergic rhinitis 1 (2) 0 (0)
Skin disorders 3 (6) 3 (7)
Acne 1 (2) 0 (0)
Contact dermatitis 1 (2) 0 (0)
Eczema 0 (0) 1 (2)
General 3 (6) 2 (5)
Fever 1 (2) 1 (2)
Fatigue 1 (2) 0 (0)
NOTE. Values are expressed as n (%).
TEAE, treatment-emergent adverse event.
aEpisode of food poisoning, deemed not related to the study drug.
bDue to chest pain, dyspnea, nausea, and vomiting, deemed related to the study drug.
Supplementary Table 3.Morning Serum Cortisol Results
in Patients With Eosinophilic
Esophagitis Receiving Budesonide
Oral Suspension and Placebo
BOSa Placeboa
Absolute value, mg/dL, mean ± SD
Baseline visit 10.4 ± 3.9 10.9 ± 4.3
After 4 wks of study drug 10.1 ± 4.3 12.0 ± 11.1
End of treatment 9.6 ± 4.2 11.3 ± 4.6
Change from baseline, mg/dL,
mean ± SD
After 4 wks of study drug 0.3 ± 5.0 1.2 ± 3.0
End of treatment 0.7 ± 4.4 0.4 ± 4.2
Below the lower limit of normal, n (%)
Baseline visit 0 (0) 0 (0)
After 4 wks of study drug 3 (6) 1 (2)
End of treatment 3 (6) 2 (5)
aBaseline, 4-wk, and end-of-treatment data were available for
49, 50, and 51 patients in the BOS group, and 42, 41, and 42
patients in the placebo group.
Supplementary Table 4.Growth Characteristics in Patients
With Eosinophilic Esophagitis





Total number 17 14
Mean ± SD 4.0 ± 4.8 5.8 ± 3.4





Total number 18 15
Mean ± SD 0.15 ± 0.52 0.03 ± 0.60
Median (range) 0.17 (0.70 to 1.00) 0.12 (1.16 to 0.86)
End of treatment
Total number 17 14
Mean ± SD 0.31 ± 0.60 0.16 ± 0.57
Median (range) 0.23 (0.55 to 1.64) 0.35 (0.99 to 1.02)
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